pharmaceutical daily

Clinical Studies of EIDD-2801 for the Treatment of Patients with COVID-19 are Underway KENILWORTH, N.J. & MIAMI–(BUSINESS WIRE)–$MRK #COVID19–Merck (NYSE:…

Clinical Studies of EIDD-2801 for the Treatment of Patients with COVID-19 are Underway KENILWORTH, N.J. & MIAMI–(BUSINESS WIRE)–$MRK #COVID19–Merck (NYSE:…

New Collaboration to Leverage Complementary Expertise and Capabilities with rVSV Technology to Advance Novel Vaccine Candidate KENILWORTH, N.J. & NEW…

New Collaboration to Leverage Complementary Expertise and Capabilities with rVSV Technology to Advance Novel Vaccine Candidate KENILWORTH, N.J. & NEW…

New Collaboration to Leverage Complementary Expertise and Capabilities with rVSV Technology to Advance Novel Vaccine Candidate KENILWORTH, N.J. & NEW…

Merck to Apply its Industry-Leading Vaccine Development Capabilities to SARS-CoV-2 Vaccine Program Originated by Themis and Institut Pasteur KENILWORTH, N.J.–(BUSINESS…

Merck to Apply its Industry-Leading Vaccine Development Capabilities to SARS-CoV-2 Vaccine Program Originated by Themis and Institut Pasteur KENILWORTH, N.J.–(BUSINESS…

Merck to Apply its Industry-Leading Vaccine Development Capabilities to SARS-CoV-2 Vaccine Program Originated by Themis and Institut Pasteur KENILWORTH, N.J.–(BUSINESS…

KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, will today announce three significant…

KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, will today announce three significant…